Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

NCT00977470 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Hydroxychloroquine

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]